Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
RCEL 
Avita Medical Ltd (RCEL)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/27/2025: RCEL (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
4 Analysts rated it
These Stocks/ETFs, based on Upturn Advisory, have historically outperformed the market, making them a top-tier choice for investors.
Year Target Price $16.85
Year Target Price $16.85
| 3 | Strong Buy |
| 0 | Buy |
| 1 | Hold |
| 0 | Under performing |
| 0 | Sell |
Analysis of Past Performance
Type Stock | Historic Profit -51.18% | Avg. Invested days 27 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/27/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 144.07M USD | Price to earnings Ratio - | 1Y Target Price 16.96 |
Price to earnings Ratio - | 1Y Target Price 16.96 | ||
Volume (30-day avg) - | Beta 1.55 | 52 Weeks Range 4.71 - 14.16 | Updated Date 06/29/2025 |
52 Weeks Range 4.71 - 14.16 | Updated Date 06/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.19 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -79.61% | Operating Margin (TTM) -63.88% |
Management Effectiveness
Return on Assets (TTM) -38.35% | Return on Equity (TTM) -407.5% |
Valuation
Trailing PE - | Forward PE 5.12 | Enterprise Value 162323886 | Price to Sales(TTM) 2.01 |
Enterprise Value 162323886 | Price to Sales(TTM) 2.01 | ||
Enterprise Value to Revenue 2.27 | Enterprise Value to EBITDA -6.17 | Shares Outstanding 26434700 | Shares Floating 25824546 |
Shares Outstanding 26434700 | Shares Floating 25824546 | ||
Percent Insiders 0.83 | Percent Institutions 26.86 |
Analyst Ratings
Rating 4.5 | Target Price 16.85 | Buy - | Strong Buy 3 |
Buy - | Strong Buy 3 | ||
Hold 1 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Avita Medical Ltd
Company Overview
History and Background
Avita Medical Ltd (formerly Clinical Cell Culture) was founded in 1993. It focuses on regenerative medicine solutions for skin restoration. Its key milestone includes FDA approval of the RECELL System.
Core Business Areas
- Wound Care: Development and commercialization of regenerative medicine products for acute and chronic wounds, including burns, trauma injuries, and surgical wounds.
Leadership and Structure
The leadership team includes Jim Corbett (CEO). Avita Medical operates with a functional organizational structure focused on research, development, and commercialization.
Top Products and Market Share
Key Offerings
- RECELL System: The RECELL System is Avita Medical's flagship product. It enables healthcare professionals to produce Spray-On Skin Cellsu2122 at the point of care. It is used to treat thermal burn wounds. The market share is growing but is not specifically broken out as of 2023, but estimates put it as 25% of the acute burn care TAM. Competitors include traditional skin grafting and synthetic skin substitutes from companies like Integra LifeSciences (IART).
Market Dynamics
Industry Overview
The regenerative medicine market is growing rapidly, driven by increasing demand for advanced wound care solutions and advancements in cell-based therapies.
Positioning
Avita Medical is positioning itself as a leader in regenerative medicine for wound care with its RECELL System, offering a less invasive alternative to traditional skin grafting.
Total Addressable Market (TAM)
The TAM for burn and wound care is estimated to be in the billions of dollars. Avita Medical is positioned to capture a significant portion through expanded applications of the RECELL System.
Upturn SWOT Analysis
Strengths
- Innovative RECELL System technology
- FDA approved product
- Strong clinical data supporting efficacy
- Growing adoption in burn centers
- Reduced need for skin grafting
Weaknesses
- Limited product portfolio
- High dependence on RECELL System sales
- Relatively small company size
- Requires specialized training for use
- Regulatory hurdles for new applications
Opportunities
- Expansion into new wound care applications (e.g., chronic wounds)
- Geographic expansion into international markets
- Development of new regenerative medicine products
- Strategic partnerships and collaborations
- Increased awareness and adoption of RECELL System
Threats
- Competition from established wound care companies
- Reimbursement challenges from healthcare payers
- Potential for technological disruptions
- Negative clinical trial results
- Economic downturn impacting healthcare spending
Competitors and Market Share
Key Competitors
- IART
- Smith & Nephew (SNN)
- MOLN
Competitive Landscape
Avita Medical has a competitive advantage with its RECELL System, but faces competition from larger, more established companies with broader product portfolios.
Growth Trajectory and Initiatives
Historical Growth: Avita Medical has experienced significant revenue growth driven by increased adoption of the RECELL System.
Future Projections: Analysts project continued revenue growth as Avita Medical expands into new markets and applications, but profitability is still a key focus.
Recent Initiatives: Recent initiatives include expanding the sales force, conducting clinical trials for new indications, and securing reimbursement agreements.
Summary
Avita Medical is a promising regenerative medicine company with an innovative product, the RECELL System, for wound care. Revenue is growing, but profitability remains a challenge. The company needs to watch out for competition from larger players and reimbursement pressures. They are expanding into new markets which is helping them gain momentum and market awareness. They should continue to focus on partnerships and new applications for RECELL.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Avita Medical Ltd Investor Relations
- Company SEC Filings
- Market Research Reports
- Analyst Estimates
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Data may be outdated; refer to official company documents for accurate information. Market share data are estimates and may vary.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Avita Medical Ltd
Exchange NASDAQ | Headquaters Valencia, CA, United States | ||
IPO Launch date 2019-10-01 | CEO, President & Executive Director Mr. James M. Corbett | ||
Sector Healthcare | Industry Medical Devices | Full time employees 260 | Website https://avitamedical.com |
Full time employees 260 | Website https://avitamedical.com | ||
AVITA Medical, Inc., together with its subsidiaries, operates as a therapeutic acute wound care company in the United States, Japan, the European Union, Australia, and the United Kingdom. The company's lead product is the RECELL System, a cell harvesting device used for the treatment of thermal burn wounds and full-thickness skin defects, as well as for repigmentation of stable depigmented vitiligo lesions. It also provides RECALL autologous cell harvesting device, which can treat areas of up to 1,920 cm2; RECELL autologous cell harvesting device with ease-of-use, an enhanced ease-of-use device that can treat areas of up to 1,920 cm²; and RECELL GO mini autologous cell harvesting device, a line extension of the RECELL GO system to treat smaller wounds up to 480 cm2, as well as RECELL GO autologous cell harvesting device consisting of RECELL GO processing device, which controls and manages the pressure applied to disaggregate the donor skin cells and controls the incubation time of the RECELL Enzyme to optimize cell yield and promote cell viability; and RECELL GO preparation kit, which can treat areas up to 1,920 cm2. In addition, the company markets, sells, and distributes PermeaDerm, a biosynthetic wound matrix; and Cohealyx, a collagen-based dermal matrix. It serves hospitals, treatment centers, and distributors. The company was formerly known as AVITA Therapeutics, Inc. and changed its name to AVITA Medical, Inc. in December 2020. AVITA Medical, Inc. is headquartered in Valencia, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.